Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2010-12-30 Governance Information
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Share Trading Policy 7 pages 68.4KB
Governance Information Classification · 95% confidence The document is titled 'PHOSPHAGENICS LIMITED - SHARE TRADING POLICY' and contains detailed rules and procedures regarding insider trading, dealing in company securities, blackout periods, and clearance requirements for directors and employees. It is a policy document related to corporate governance and insider trading compliance. There is no financial data, earnings information, or report content. It is not an announcement of a report but a governance-related policy document. Therefore, the most appropriate classification is Governance Information (CGR).
2010-12-30 English
Phosphagenics Collaborates With 3M To Develop Pain Patch 1
Regulatory Filings Classification · 95% confidence The document is a company announcement about a collaboration agreement between Phosphagenics and 3M to develop a pain patch. It provides details about the agreement, company background, and contact information. There is no financial data, regulatory filing references, or report attachments. The content is an update on a business development or partnership rather than a financial report, management change, or regulatory filing. Therefore, it fits best under Regulatory Filings (RNS) as a general company announcement that does not fit other specific categories.
2010-11-15 English
November 2010 Newsletter 4 pages ?Kb
Investor Presentation Classification · 90% confidence The document is a newsletter from Phosphagenics Limited dated November 2010. It contains updates on research and development, product pipeline, clinical trials, commercial partnerships, and marketing activities. There are no financial statements, regulatory certifications, voting results, or formal announcements of filings. The content is primarily informational and promotional, aimed at shareholders and interested parties, summarizing recent progress and future plans. It does not fit the definitions of formal financial reports, regulatory filings, or meeting materials. Given the nature and content, this document best fits the category of Investor Presentation (IP), as it provides detailed information on company strategy, product development, and market positioning for investors and shareholders.
2010-11-08 English
CZD: Calzada signs Licensing deal with Phosphagenics 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a press release announcing a licensing deal between Calzada Limited and Phosphagenics Limited to commercialize a cosmeceutical product using a specific technology. It discusses product development, market potential, and future plans but does not contain any financial statements, regulatory filings, or detailed financial data. The document length is 4310 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is an annual report, earnings release, or any other formal financial filing. It is primarily a corporate announcement about a commercial agreement and product development. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2010-10-18 English
Anti-fat Peptide Patch progresses - product sales early 2011 2 pages ?Kb
Capital/Financing Update Classification · 85% confidence The document is a company announcement about a licensing deal and commercial strategy for a new cosmeceutical product using TPM technology. It discusses product development, market potential, and future plans but does not contain financial statements, regulatory filings, or detailed financial data. The length is 3638 characters, which is relatively short and the content is promotional and strategic rather than financial or regulatory. There is no indication of an earnings release, annual or interim report, or any regulatory filing. This fits best as a Capital/Financing Update (CAP) since it relates to a licensing deal and commercial progress, which are financing and capital-related updates for investors.
2010-10-18 English
Preparation- pain patch manufacturing after positive results 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a press release announcing Phosphagenics' progress towards commercial scale-up of a drug delivery patch after positive clinical trial results. It discusses clinical trial phases, manufacturing plans, and future development steps. There are no financial statements, regulatory certifications, voting results, or detailed financial data. The content is primarily an update on product development and company progress rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The document is best classified as a general regulatory announcement or company update that does not fit other specific categories, thus falling under Regulatory Filings (RNS). The document length is under 5,000 characters and is a standalone announcement, not a report publication announcement or certification.
2010-10-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.